Ronen Luzon - Jul 13, 2023 Form 4 Insider Report for My Size, Inc. (MYSZ)

Signature
/s/ Ronen Luzon
Stock symbol
MYSZ
Transactions as of
Jul 13, 2023
Transactions value $
$0
Form type
4
Date filed
7/17/2023, 05:05 PM
Previous filing
Oct 3, 2022
Next filing
Dec 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYSZ Option to purchase Common Stock (right to buy) Disposed to Issuer -6.4K -100% 0 Jul 13, 2023 Common Stock, $.001 par value per share 6.4K $26.00 Direct F1, F2
transaction MYSZ Option to purchase Common Stock (right to buy) Award +6.4K 6.4K Jul 13, 2023 Common Stock, $.001 par value per share 6.4K $1.09 Direct F1, F2
transaction MYSZ Option to purchase Common Stock (right to buy) Disposed to Issuer -1.6K -100% 0 Jul 13, 2023 Common Stock, $.001 par value per share 1.6K $26.00 Direct F1, F2
transaction MYSZ Option to purchase Common Stock (right to buy) Award +1.6K 1.6K Jul 13, 2023 Common Stock, $.001 par value per share 1.6K $1.09 Direct F1, F2
transaction MYSZ Option to purchase Common Stock (right to buy) Disposed to Issuer -5.2K -100% 0 Jul 13, 2023 Common Stock, $.001 par value per share 5.2K $26.00 See footnote F1, F2, F3
transaction MYSZ Option to purchase Common Stock (right to buy) Award +5.2K 5.2K Jul 13, 2023 Common Stock, $.001 par value per share 5.2K $1.09 See footnote F1, F2, F3
transaction MYSZ Option to purchase Common Stock (right to buy) Disposed to Issuer -894 -100% 0 Jul 13, 2023 Common Stock, $.001 par value per share 894 $26.00 See footnote F1, F2, F3
transaction MYSZ Option to purchase Common Stock (right to buy) Award +894 894 Jul 13, 2023 Common Stock, $.001 par value per share 894 $1.09 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested.
F2 Effective July 13, 2023, the Board of Directors of the Company approved a unilateral option repricing, which resulted in the reduction of the exercise price to $1.09 per share, which is the closing price of the Company's common stock on July 13, 2023. All of the other terms of the option remained unchanged.
F3 Options acquired by Spouse (Chief Product Officer and Chief Operating Officer Billy Pardo).

Remarks:

On December 8, 2022, the Company implemented a 1-for-25 reverse stock split (the "Reverse Stock Split") of the Company's common stock. All amounts have been adjusted to give effect to the Reverse Stock Split.